Endometrial cancer (EC) is third or second and in some places most common cancer amongst women globally. It contributes to 6% of cancers in women and is one of the most frequently diagnosed gynaecologic cancers. EC cases have been divided into two types, because of differences in risk factors, presentation, histopathology and behavior. Type I Adenocarcinoma, most common variety associated with endometrial hyperplasia (EH), unopposed estrogenic stimulation without adequate opposition by progestin and Type II, serous carcinoma, clear cell carcinoma, anaplastic carcinoma in atrophic endometrium in older women, high risk histologic types. Over the years researchers have recognized many risk factors for EC, like elderly age, nulliparity, infertility, early menarche, late menopause: obesity, diabetes, hypertension, Insulin resistance, dyslipidaemia, polycystic ovary syndrome (PCOS), unopposed estrogen therapy, animal origin nutrients, families with hereditary nonpolyposis of colon cancer and long-term Tamoxifen therapy in breast cancer.
